• CoronaCoronavirus (COVID-19) Resources

    In an effort to support our members with the most updated information on COVID-19 we developed this resource page to easily access current CDC information and other resources to assist you professionally and personally.

    We will continue to update this page with more information as it becomes available and welcome your input as we navigate through this situation. As health care professionals it is our job to educate our patients and families on prevention and the what to do if someone is symptomatic.

    View resources


  • 2020 GAPNA Pharmacology Conference: Contemporary Pharmacology and Prescribing in Older AdultsGAPNA Pharmacology Conference:
    Contemporary Pharmacology and Prescribing in Older Adults

    Rescheduled, so you won't miss a thing! Find out what to do next!

    April 20-24, 2021, Honolulu, Hawaii

    More Information

  • AwardCall for Excellence Award Nominations

    The awards are: Emerging Chapter Award, Established Chapter Excellence Award, Special Interest Group Excellence Award, Excellence in Clinical Practice Award, Excellence in Community Service Award, Excellence in Education Award, Excellence in Leadership Award, and Excellence in Research Award.

    The nominations are tallied in July and the winners are announced every year during the Awards Celebration at the GAPNA Annual Conference.

    Now is the time to nominate a colleague or yourself - DEADLINE is June 1, 2020.

    Get started... nominate today!

  • FREE CE for GAPNA MembersFREE continuing education credit is available for the following session:

    "Safety and Utility of Cannabis in the Elderly"

    (session captured at the GAPNA 2018 Annual Conference)

    For March/April 2020 - Get Your Free CNE Now!

Elderly Patients with Colon Cancer at Risk for Various Treatment-Related Toxicities

Patients who receive surgery for stage III colon cancer can benefit from 5-flurouracil (5-FU)-based chemotherapy.

However, 5-FU-based chemotherapy is associated with increased risk of developing gastrointestinal, blood, and cardiac toxicities in elderly patients with colon cancer. These patients need to be monitored closely so that the benefits of chemotherapy can outweigh the risks, suggest the study authors.

In a study of 12,099 patients with stage III colon cancer, patients receiving chemotherapy were more likely to be younger, married, and have fewer coexisting conditions than the untreated group.

This difference was most pronounced for age, with 88.2% of patients aged 65-69 initiating chemotherapy compared to just 18.1% of patients aged 85 and older.

During 3 months after surgery, the cumulative incidence rate of toxicities was 9.1% in the chemotherapy group and 4.3% in the non-chemotherapy group.

Common toxicities included volume depletion disorder, agranulocytosis, diarrhea, nausea, and vomiting. Women were 35% more likely to experience toxicities than men and Blacks were 35% less likely to develop toxicities than Whites.

Chemotherapy was only slightly associated with the risk for developing heart disease.

For more info, see Hu, C-Y. et al. (2012). Adjuvant chemotherapy and risk of gastrointestinal, hematologic, and cardiac toxicities in elderly patients with stage III colon cancer. American Journal of Clinical Oncology, 35(3), 228-236.

Related Topic 1: 

GAPNA Newsletter Issue: